CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Test - xHyA +1 moredrug
Likely dose
Test - xHyA 1.2 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07458685
NCT07458685N/ACompleted

Efficacy of Cross-linked Hyaluronic Acid in Improving Healing After Free Gingival Graft: a Randomized Controlled Clinical Trial

University of Milan·interventional·Posted Mar 9, 2026·Updated Mar 9, 2026

In Brief

A clinical study evaluating Test - xHyA and Negative control for Palatal Donor Site Wound Healing and Palatal Wound. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The goal of this study is to evaluate the use of a gel containing cross-linked hyaluronic acid (xHyA) at the palatal donor site following soft tissue harvesting procedures. The main questions it aims to answer are: 1) Does the use of xHyA improve post-operative patient morbidity?; 2) Does the use of xHyA improve palatal donor site healing? Researchers will compare xHyA topically applied at the palatal donor site to a negative control to see if xHyA works to minimize participants' morbidity and improve clinical healing. Participants will be equally distributed into two groups, half of them receiving xHyA. Participants will fill a visual analogue scale for subjective analyses during the first 2 post-operative weeks and will visit the dental clinic at 3, 7, 14 and 60 post-operative days for checkups and clinical examinations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly

Timeline

N/ACompletedFinished
2023202420252026
First PostedMar 9, 2026
Enrollment StartSep 5, 2022
Primary CompletionJul 24, 2025
Study CompletionOct 2, 2025
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 4 months ago

Interventions

Test - xHyAdrug

The xHyA gel is contained in a 1.2 mL sterile cartridge containing highly purified 1.6% high molecular weight cross-linked HA and 0.2% natural HA to be injected with a 23G blunt needle. The xHyA gel is applied directly over the exposed connective tissue at the donor area and injected inside a resorbable collagen sponge that is stabilized to the donor site with silk sutures. No further applications of xHyA are planned during the study.

Negative controlother

A dry collagen sponge not loaded with xHyA is adapted and stabilized to the donor area with a 4-0 silk cross mattress suture.